← All trials
NCT04355936
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- Oct 1, 2020
- Completion date
- Oct 1, 2020
- First posted
- Apr 21, 2020
- Last posted
- May 14, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorio Elea S.A.C.I.F. y A.Lead sponsor
- University of Buenos AiresStudy chair
- University of Buenos AiresOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.